Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study.
A prospective survey was performed to characterize the prevalence of sleep attacks and to evaluate precipitating factors in a group of 236 patients with idiopathic Parkinson's disease. Sleep attacks were reported by 72 patients (30.5%). Multivariate analysis showed a marked association between the occurrence of sudden sleep episodes and first autonomic failure, followed by treatment with ropinirole and bromocriptine. The present work underlines the major contributing role of autonomic failure followed by dopamine agonists in the occurrence of such an event. Because a relationship between sleep attacks and not only ropinirole but also bromocriptine treatment was described, the present work suggests that sleep attacks are a common side effect of all dopamine agonists.
Montastruc
J L
JL
Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Faculté de Médecine, Toulouse, France.
Brefel-Courbon
C
C
Senard
J M
JM
Bagheri
H
H
Ferreira
J
J
Rascol
O
O
Lapeyre-Mestre
M
M
D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001342:Autonomic Nervous System Diseases / Q000139:chemically induced; D006970:Disorders of Excessive Somnolence / Q000139:chemically induced* / Q000453:epidemiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010300:Parkinson Disease / Q000188:drug therapy / Q000453:epidemiology; D017891:Pharmacoepidemiology; D010865:Pilot Projects
D000978:Antiparkinson Agents